On Thursday, Shares of Abbott Laboratories (NYSE:ABT), surged 2.82% to $41.87.
New York Road Runners and global healthcare company Abbott (ABT) will partner for the 2015 TCS New York City Marathon, set for Sunday, Nov. 1. The partnership complements Abbott’s existing title sponsorship of the global Abbott World Marathon Majors.
“New York Road Runners’ planned partnership with Abbott on the TCS New York City Marathon builds on existing synergies between the two organizations,” said John Gassner, vice president of business development and planned partnerships for New York Road Runners. “Both organizations passionately promote a lifestyle inspired by fitness and achieving the highest level of health and wellness among people of all ages. As title sponsor of the Abbott World Marathon Majors, Abbott’s new involvement with the TCS New York City Marathon further connects the dots to a series of first-class events in the endurance space.”
Abbott’s corporate identity, “LIFE. TO THE FULLEST.,” aligns with New York Road Runners’ mission of assisting to inspire people through running. Abbott is devoted to developing products and technologies that improve the health and lives of many, and celebrates how people, when at their healthiest, can do more, achieve more, and experience more in life.
The partnership comprises the use of 15 i-STAT® systems, handheld blood analyzers that perform commonly ordered blood tests within minutes. The i-STAT® devices, which Abbott is deploying across all Abbott World Marathon Majors races, empower medical personnel to better administer needed care on site.
Abbott supports tens of thousands of marathon participants and encourages the sharing of health “best practices” among the six iconic races that make up the series, counting the Tokyo Marathon, Boston Marathon, Virgin Money London Marathon, BMW Berlin-Marathon, Bank of America Chicago Marathon, and TCS New York City Marathon.
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon.
On other hand, Shares of Boston Scientific Corporation (NYSE:BSX), surged 1.14% to $16.85.
Boston Scientific Corporation’s shares are trading 0.27% above their 50-day moving average, and -0.25% below their 200-day moving average. The stock recently closed at market price of $16.85 with a 1 year price target of $20.33. It is up 47.29% over 12 months and trades at 15.94 times forward earnings. The total volume gained by the company was 7,432,700, lower as compared to its average daily volume of 8.41M shares. The company has the beta value of 1.00.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
